Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is 1 of the most promising stocks with immense upside potential. On November 24, Barclays expert Gena Wang lowered the firm’s terms people connected Ultragenyx (RARE) to $50 from $81 and maintained an Overweight standing connected the shares. The steadfast lowered its terms people pursuing investigation of the setrusumab COSMIC study, but inactive maintains an implicit 70% accidental of a affirmative result.

Earlier the aforesaid month, Ultragenyx Pharmaceutical reported that it made a full gross of $160 cardinal successful Q3 2025, which marked a 15% maturation year-over-year. The institution is present connected way to present full-year gross betwixt $640 and $670 million, which represents a maturation of 14% to 20% implicit 2024. Revenue maturation was driven by its cardinal commercialized products. Crysvita Revenue accounted for $112 cardinal successful Q3. The full-year Crysvita gross guidance is expected betwixt $460 and $480 million, a 12% to 17% maturation implicit 2024, contempt the short-term interaction from expected seasonality connected royalty revenue. AJOVY Revenue for the 4th was $24 million, and Mepsevii Revenue was $7 million.

The institution besides reported a nett nonaccomplishment of $180 cardinal oregon $1.81 per stock for Q3. Ultragenyx is present aggressively advancing aggregate late-stage objective programs with transformative commercialized potential, including UX 143 (setrusumab) and GTX-102. Submissions for different pipeline assets are besides connected track, with DTX401 expected for submission adjacent month, portion the submission for UX 111 was somewhat delayed owed to requirements for further reports.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is simply a biopharmaceutical institution that identifies, acquires, develops, and commercializes caller products for the attraction of uncommon and ultra-rare familial diseases successful North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

While we admit the imaginable of RARE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.